Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer.
Portale F, Carriero R, Iovino M, Kunderfranco P, Pandini M, Marelli G, Morina N, Lazzeri M, Casale P, Colombo P, De Simone G, Camisaschi C, Lugli E, Basso G, Cibella J, Marchini S, Bordi M, Meregalli G, Garbin A, Dambra M, Magrini E, Rackwitz W, Cecconi F, Corbelli A, Fiordaliso F, Eitler J, Tonn T, Di Mitri D. Portale F, et al. Among authors: meregalli g. Nat Commun. 2024 Nov 28;15(1):10343. doi: 10.1038/s41467-024-54355-2. Nat Commun. 2024. PMID: 39609420 Free PMC article.
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study.
European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). Lancet Diabetes Endocrinol. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3. Epub 2024 Oct 4. Lancet Diabetes Endocrinol. 2024. PMID: 39374602 Free article.
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A; GLIMPLES study investigators. Fadini GP, et al. Among authors: meregalli g. Diabetes Obes Metab. 2024 Jun;26(6):2390-2400. doi: 10.1111/dom.15554. Epub 2024 Mar 13. Diabetes Obes Metab. 2024. PMID: 38477183
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
Casula M, Gazzotti M, Capra ME, Olmastroni E, Galimberti F, Catapano AL, Pederiva C; LIPIGEN Group and the LIPIGEN Paediatric Group. Casula M, et al. Atherosclerosis. 2023 Nov;385:117231. doi: 10.1016/j.atherosclerosis.2023.117231. Epub 2023 Aug 12. Atherosclerosis. 2023. PMID: 37648636 Free article.
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.
Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Rossing P, et al. Diabetes Care. 2023 Sep 1;46(9):1721. doi: 10.2337/dc23-er09. Diabetes Care. 2023. PMID: 37310695 Free PMC article. No abstract available.
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Sarafidis P, et al. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7. Clin J Am Soc Nephrol. 2023. PMID: 36927680 Free PMC article. Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
39 results